MONISTAT 7 COMBINATION PACK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MONISTAT 7 COMBINATION PACK (MONISTAT 7 COMBINATION PACK).
Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, preventing conversion of lanosterol to ergosterol, thereby disrupting fungal cell membrane synthesis.
| Metabolism | Minimal systemic absorption; primarily metabolized in the liver via oxidative pathways. |
| Excretion | Miconazole is primarily metabolized in the liver; less than 1% of absorbed dose is excreted unchanged in urine. Fecal excretion accounts for approximately 50% of the dose, primarily as metabolites. Biliary excretion is minimal. |
| Half-life | Terminal elimination half-life is approximately 24 hours for miconazole after systemic absorption, reflecting slow tissue redistribution and hepatic clearance. After intravaginal administration, systemic absorption is minimal (<1.4%), so half-life is not clinically relevant. |
| Protein binding | Miconazole is 90–93% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution (Vd) is approximately 20–30 L/kg, indicating extensive tissue penetration and distribution into peripheral compartments such as skin and mucous membranes. |
| Bioavailability | Intravaginal: Systemic bioavailability is <1.4% after vaginal administration. Oral: Not formulated for systemic use; oral bioavailability is low (<25%) due to extensive first-pass metabolism. |
| Onset of Action | Intravaginal: Symptom relief (itching, burning) begins within 24–48 hours after application. Complete resolution of infection typically requires 7 days. |
| Duration of Action | Intravaginal: Suppository provides sustained release over 24 hours; clinical effects persist for the treatment duration of 7 days. The cream provides rapid relief but is reapplied daily. |
| Molecular Weight | 416.13 |
Intravaginal: one applicatorful (200 mg miconazole nitrate) at bedtime for 7 nights. Also: topical cream (2%) applied to affected area twice daily for 7 days.
| Dosage form | CREAM, SUPPOSITORY |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for Child-Pugh A or B. For Child-Pugh C, use with caution due to limited data. |
| Pediatric use | Children ≥12 years: same as adult. Children <12 years: safety not established; use only under medical supervision. |
| Geriatric use | No specific dose adjustment; same as adult dosing. Monitor for local irritation. |
| 1st trimester | Miconazole is generally avoided in the first trimester unless essential; limited data suggest low risk, but alternative treatments are preferred. |
| 2nd trimester | Considered safe for use; topical miconazole is minimally absorbed and unlikely to cause fetal harm. |
| 3rd trimester | Considered safe for use; same rationale as second trimester. |
Clinical note
Comprehensive clinical and safety monograph for MONISTAT 7 COMBINATION PACK (MONISTAT 7 COMBINATION PACK).
| Placental transfer | Minimal to negligible based on low systemic absorption (less than 2%) after topical or vaginal administration. |
| Breastfeeding | Miconazole is poorly absorbed from skin and vagina; systemic levels are negligible. Use is considered compatible with breastfeeding. Avoid application to breast area to prevent infant ingestion. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to miconazole or any componentKnown hypersensitivity to other azole antifungals
| Precautions | For intravaginal use only, Do not use if abdominal pain, fever, or foul-smelling discharge present, Discontinue if irritation or sensitization occurs, Do not use during menstruation, If no improvement within 3 days, re-evaluate diagnosis |
| Food/Dietary | No clinically significant food interactions. However, high-sugar diets may promote Candida growth; consider limiting sugar intake. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L2 (Safer) |
| Teratogenic Risk | FDA Pregnancy Category C (pre-2015). Miconazole use in first trimester has been associated with a small increased risk of spontaneous abortion in some observational studies, but no consistent evidence of major congenital malformations. Vaginal absorption is minimal (1-2%); systemic exposure is low. Risk appears minimal, but use only if clearly needed, especially in first trimester. |
| Fetal Monitoring | No specific maternal or fetal monitoring required beyond routine prenatal care. If signs of systemic toxicity (allergy, irritation) occur, discontinue use. |
| Fertility Effects | No known adverse effects on fertility. Intravaginal miconazole does not affect ovulation, conception, or implantation. Treatment of vulvovaginal candidiasis may improve fertility by resolving infection-related inflammation. |
| Monistat 7 Combination Pack contains miconazole nitrate (200 mg suppository) and miconazole nitrate 2% cream. For vulvovaginal candidiasis, the 7-day regimen is preferred in pregnancy. Use of the suppository may cause vaginal discharge; the cream is for external use only. Caution in patients with hypersensitivity to azoles. Do not use with condoms or diaphragms due to potential damage. |
| Patient Advice | Insert one suppository intravaginally at bedtime for 7 consecutive nights. · Apply a small amount of cream to the external genital area twice daily as needed. · Complete the full 7-day treatment even if symptoms improve. · Avoid sexual intercourse during treatment to prevent reinfection or irritation. · Do not use tampons, douches, or other vaginal products during therapy. · Wash hands before and after insertion. · If no improvement in 3 days, consult your healthcare provider. · Pregnant women should consult a doctor before use. · This product may damage condoms and diaphragms; use alternative contraception. |